Today, leading developer of immunotherapies for cancer and other diseases, Advaxis, announced that it has published the preclinical research for ADXS-HPV, Advaxis’ Lm-LLO lead drug candidate. The product is designed for use in the treatment of HPV-associated cancers in combination with the PD-1 antibody.
The paper, titled “Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy,” has been e-published in the Journal for Immunotherapy of Cancer. Dr. Samir N. Khleif and his research team conducted the research at the Georgia Regents University Cancer Center. Advaxis provided the Lm-LLO immunotherapies and partial research funding.
Among the studies’ various findings, it was demonstrated that treatment with an Lm-LLO immunotherapy, in combination with an anti-PD-1 antibody, significantly improved immune and therapeutic efficacy in preclinical mouse models.
The study also showed that a significant reduction of regulatory T cells and myeloid-derived suppressor cells in spleen and tumor microenvironments were mediated solely by the Lm-LLO immunotherapy. The addition of anti-PD-1 antibody to the Lm-LLO immunotherapy treatment resulted in an increase in antigen-specific immune responses in the periphery and in CD8 T cell infiltration into the tumor. As a result, this treatment combination led to inhibition of tumor growth and prolonged survival, while also completing regression of tumors, in treated animals.
Based on the findings in the mouse model, the team conducted additional studies to evaluate activity in human cells. Lm-LLO immunotherapy treatment was found to significantly upregulate surface PD-L1 expression on human monocyte-derived dendritic cells isolated. This finding suggests that the combination of Lm-LLO immunotherapy with an anti-PD-1 antibody could have clinical application.
“Previous studies with Lm-LLO immunotherapies have established the ability to combine with chemotherapy and radiation. Dr. Khleif’s data are first to show the potential of combining Advaxis constructs with promising immune modulator (PD-1) in active clinical development,” commented Dr. Petit, Chief Scientific Officer of Advaxis.
For more information, visit www.advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment